Rescue of a pathogenic mutant human glucagon receptor by pharmacological chaperones

Run Yu, Chun-Rong Chen, Xiaohong Liu1 and János T Kodra2

Division of Endocrinology and Carcinoid and Neuroendocrine Tumor Center, Cedars-Sinai Medical Center, B-131, 8700 Beverly Boulevard, Los Angeles, California 90048, USA
1Gilead Sciences, Foster City, California, USA
2Novo Nordisk A/S, Novo Nordisk Park, Måløv, Denmark

(Correspondence should be addressed to R Yu; Email: run.yu@cshs.org)

Abstract

We have previously demonstrated that a homozygous inactivating P86S mutation of the glucagon receptor (GCGR) causes a novel human disease of hyperglucagonemia, pancreatic \( \alpha \)-cell hyperplasia, and pancreatic neuroendocrine tumors (Mahvash disease). The mechanisms for the decreased activity of the P86S mutant (P86S) are abnormal receptor localization to the endoplasmic reticulum (ER) and defective interaction with glucagon. To search for targeted therapies for Mahvash disease, we examined whether P86S can be trafficked to the plasma membrane by pharmacological chaperones and whether novel glucagon analogs restore effective receptor interaction. We used enhanced green fluorescent protein-tagged P86S stably expressed in HEK 293 cells to allow fluorescence imaging and western blotting and molecular modeling to design novel glucagon analogs in which alanine 19 was replaced with serine or asparagine. Incubation at 27 °C largely restored normal plasma membrane localization and normal processing of P86S but osmotic chaperones had no effects. The ER stressors thapsigargin and curcumin partially rescued P86S. The lipophilic GCGR antagonist L-168,049 also partially rescued P86S, so did Cpd 13 and 15 to a smaller degree. The rescued P86S led to more glucagon-stimulated cAMP production and was internalized by glucagon. Compared with the native glucagon, the novel glucagon analogs failed to stimulate more cAMP production by P86S. We conclude that the mutant GCGR is partially rescued by several pharmacological chaperones and our data provide proof-of-principle evidence that Mahvash disease can be potentially treated with pharmacological chaperones. The novel glucagon analogs, however, failed to interact with P86S more effectively.

Journal of Molecular Endocrinology (2012) 49, 69–78

Introduction

The pancreatic islet hormone glucagon is secreted by \( \alpha \)-cells and regulates blood glucose levels (Quesada et al. 2008, Cryer 2011). Glucagon signals through its G-protein-coupled receptor, glucagon receptor (GCGR), which belongs to the secretin receptor family (Authier & Desbuquois 2008). We have identified a novel human disease of hyperglucagonemia, \( \alpha \)-cell hyperplasia, and pancreatic neuroendocrine tumors caused by a homozygous, inactivating GCGR mutation (Mahvash disease) (Yu et al. 2008, Zhou et al. 2009). The natural mutation results in substitution of proline 86 with serine (P86S) in the N-terminal extracellular domain (ECD) of GCGR. One mechanism for the decreased activity of P86S is abnormal receptor trafficking (Zhou et al. 2009, Yu et al. 2011a). The WT GCGR is predominantly localized to the plasma membrane; however, only a small portion of P86S is appropriately processed and transported to the plasma membrane while the majority appears to be stranded in the endoplasmic reticulum (ER). Another mechanism appears to be defective interaction with glucagon.

We have further demonstrated that GCGR-deficient mice exhibit an identical phenotype to that of Mahvash disease caused by P86S (Yu et al. 2011b). In those mice, \( \alpha \)-cell hyperplasia is evident at 3 months, followed by islet dysplasia at 6–7 months, and pancreatic neuroendocrine tumors with 100% penetrance at 10–12 months. As \( \alpha \)-cell hyperplasia also occurs in animal models with deficiency of prohormone convertase 2 (resulting in failure to produce glucagon) or treated with GCGR antagonists (Furuta et al. 1997, Petersen & Sullivan 2001, Qureshi et al. 2004, Winzell et al. 2007, Yan et al. 2009), it is likely that glucagon regulates its own production by negative feedback, the removal of which by GCGR inactivating mutation or deletion causes compensatory hyperglucagonemia and \( \alpha \)-cell hyperplasia, a precursor to neuroendocrine tumors (Ouyang et al. 2011, Yu et al. 2011b).

Currently, there have been no specific therapies for Mahvash disease (Yu et al. 2008, Ouyang et al. 2011). Somatostatin analogs suppressed glucagon levels in a patient with Mahvash disease but whether they inhibit...
α-cell hyperplasia is not clear (Yu et al. 2008). As α-cell hyperplasia is reversible after restoring glucagon signaling by supplementing glucagon or withdrawal of antagonists in animal models with deletion of prohormone convertase 2 or treated with GCGR antagonists, respectively (Webb et al. 2002, Gu et al. 2009), α-cell hyperplasia is also conceivably reversible in patients with Mahvash disease, if P86S can be rescued. Mutant G-protein-coupled receptors (such as the GnRH receptor and vasopressin type 2 receptor) with abnormal, intracellular localization can be rescued by pharmacological chaperones (Janovick et al. 2002, 2003, Bernier et al. 2004, Robben et al. 2006, Oueslati et al. 2007, Jean-Alphonse et al. 2009). We therefore first examined whether P86S can be trafficked to the plasma membrane by pharmacological chaperones. Encouraged by the rational design of novel ligands for a mutant epithelial growth factor receptor (Denholt et al. 2009), we also tested whether P86S has improved interaction with novel glucagon analogs designed in silico. Our data demonstrate that P86S is partially rescued by pharmacological chaperones and provide proof-of-principle evidence that Mahvash disease can be potentially treated with pharmacological chaperones. The novel glucagon analogs, however, do not interact with P86S more effectively.

Materials and methods

Cell culture and reagents

HEK 293 cells stably expressing WT GCGR-EGFP or P86S-EGFP were described previously (Yu et al. 2011a) and grown in DMEM supplemented with 10% fetal bovine serum at 37°C (unless specified otherwise) in a humidified incubator circulated with 5% CO2. Tunicamycin, DMSO, glycerol, trimethylamine N-oxide (TMAO), 4-phenylbutyric acid (PBA), thapsigargin, curcumin, and streptavidin agarose were from Sigma; glucagon and GCGR antagonist L-168,049 from Thermo Scientific (Rockford, IL, USA). GCGR antagonists Cpd 13 and Cpd 15 were described previously (Kodra et al. 2011a, 2012) and grown in flasks with gridded bottom and the same groups of cells were visualized over time with green fluorescence filter using the grids to confirm the identity of cells.

Biotinylation and isolation of cell surface proteins

Biotinylation and isolation of cell surface proteins were performed according to the manufacturer’s recommendation (Thermo Scientific). HEK 293 cells expressing WT GCGR-EGFP or P86S-EGFP were washed, suspended in PBS (1 ml/10 cm dish with subconfluent cells), and incubated with 0.5 mg sulfo-NHS-LC-biotin at room temperature for 30 min. Cells were then washed and membrane proteins were solubilized in RIPA buffer and incubated with streptavidin agarose at 4°C overnight. The agarose beads were washed and bound proteins were eluted with SDS sample buffer.

Western blot and cAMP assay

Western blot and cAMP assay were described previously (Zhou et al. 2009, Yu et al. 2011a). Briefly, for western blot, cell or protein lysates were resolved in SDS–PAGE and transferred to PVDF membrane. Mouse anti-EGFP (Clontech) (to detect WT GCGR-EGFP or P86S-EGFP) and mouse anti-N-cadherin antibodies were used. For cAMP assay, HEK 293 cells expressing P86S-EGFP were grown in 24-well plates and pretreated with specific conditions. Cells were then incubated with Hank’s balanced salt solution containing 1 mM isobutyl methylxanthine (Sigma) and various concentrations of glucagon or novel glucagon analogs at 37°C for 1 h. Cells were lysed by freezing and thaw cycles. cAMP was measured with a LANCE cAMP kit (PerkinElmer, Waltham, MA, USA).

Design of novel glucagon analogs

As the crystal structure of glucagon-bound GCGR has not been resolved, the structures of highly homologous glucagon-like peptide 1 (GLP1) and its receptor (GLP1R) were used to design novel glucagon analogs. GLP1R N-terminal ECD/GLP1 crystal structure coordinates 3IOL (Underwood et al. 2010) was downloaded from Protein Data Bank (PDB) (http://www.rcsb.org/pdb/)
and analyzed with PyMOL, a molecular graphics system for real-time visualization and rapid generation of high-quality molecular graphics images (DeLano Scientific, San Carlos, CA, USA). The 3IOL structure file was uploaded and the ribbon views created. To illustrate the relative location and possible interactions of the side chains in the mutants, amino acid direct replacement was carried out using the ‘mutagenesis’ function without energy minimization. Alanine 25 in GLP1 corresponds to alanine 19 in glucagon, and threonine 35 and proline 90 in GLP1R correspond to phenylalanine 31 and proline 86 in GCGR respectively. Amino acid replacement on alanine 19 of the native glucagon was carried out to restore the distances of alanine 19 in glucagon to serine 86 and phenylalanine 31 in GCGR. Peptide 1 was glucagon with alanine 19 replaced with serine and peptide 2 with asparagine; both peptides were synthesized by solid-phase technology (GenScript, Piscataway, NJ, USA).

Results

Pharmacological chaperones of P86S

As there are no reliable predictors of chaperones for a given mutant receptor (Conn et al. 2007), we tested potential chaperones of P86S based on those that have been used to rescue other mutant G-protein-coupled receptors (Janovick et al. 2002, 2003, Bernier et al. 2004, Robben et al. 2006, Oueslati et al. 2007, Jean-Alphonse et al. 2009). In HEK 293 cells, WT GCGR was predominantly localized on the plasma membrane while P86S was predominantly located in the ER, as indicated by the plasma membrane marker N-cadherin and ER marker calreticulin, respectively, in colocalization experiments (Fig. 1A). Inhibition of glycosylation by tunicamycin changed the localization of the WT GCGR from plasma membrane to cytoplasmic in ~60% of cells but did not change P86S localization. Osmotic chaperones DMSO (1%), glycerol (4%),
TMAO (130–200 mM), and PBA (3–10 mM) had no visible effects on P86S localization after overnight incubation (16–20 h) (Fig. 1B). Incubation at 27°C largely restored plasma membrane localization of P86S. ER stressors thapsigargin and curcumin have been shown to rescue mutant G-protein-coupled receptors; the mechanism appears to be related to the increase in intracellular calcium levels induced by ER stressors (Robben et al. 2006, Oueslati et al. 2007). In our experiments, thapsigargin had some effects on restoring P86S plasma membrane localization but curcumin had a smaller effects (Fig. 1B). As lipophilic receptor antagonists are often chaperones of mutant receptors, we tested three lipophilic GCGR antagonists for their chaperone activity. L-168,049 treatment resulted in P86S plasma membrane localization in some cells but Cpd 13 and 15 had no visible effects on P86S localization (Fig. 1B). Corresponding to the predominant plasma membrane localization of WT GCGR and predominant ER localization of P86S, WT GCGR-EGFP migrated mainly as an 100-kD band on western blot (83.5 ± 3.5% of total amounts by densitometry), indicating the 100-kD band as the mature form (Fig. 1C). P86S-EGFP migrated mainly as a smaller, 80-kD band on western blot, presumably an immature form, with diminished amounts of the mature form (12.9 ± 0.7% by densitometry). Consistent with the results of microscopic observation, the glycosylation inhibitor tunicamycin at a higher concentration decreased the quantity of the mature 100-kD band in cells expressing either WT-GCGR-EGFP or P86S-EGFP (Fig. 1C). The osmotic chaperones, DMSO, glycerol, TMAO, and PBA did not change the ratio of the mature vs immature form of P86S. Incubation at 27°C resulted in a significant increase in the mature form of P86S (to 76.8 ± 2.6% by densitometry), so did the ER stressors thapsigargin and curcumin but to a lesser degree (to 48.7 ± 2.4 and 46.4 ± 1.4% by densitometry respectively). Lipophilic GCGR antagonists also increased the ratio of mature vs immature forms of P86S to various degrees with L-168,049 having the biggest effect. Thus, microscopic and biochemical studies consistently demonstrated that low temperature, ER stressors, and lipophilic GCGR antagonists facilitate P86S maturation and trafficking to the plasma membrane while osmotic chaperones have no effects on those processes.

To confirm the subcellular localization of WT GCGR and P86S and the trafficking of P86S to the plasma membrane by chaperones, live HEK 293 cells expressing WT GCGR-EGFP or P86S-EGFP were labeled with biotin (which binds to cell surface proteins) and biotinylated proteins isolated and detected by western blot (Fig. 1D). Consistent with the intracellular P86S localization, levels of biotinylated P86S-EGFP (on cell surface) in untreated cells were much lower than those of WT GCGR-EGFP, which was localized on the cell surface by microscopy (shown earlier); incubation at 27°C and thapsigargin increased the levels of biotinylated P86S-EGFP, in agreement with P86S trafficking to the cell surface by those two chaperones.

**Mechanisms for P86S trafficking by chaperones**

We used live cell imaging to observe the trafficking of P86S by the two most effective chaperones, low temperature and thapsigargin. Starting only 1 h after
cells were incubated at 27°C, most cells developed coarse granular aggregates of P86S-EGFP (Fig. 2). Significant plasma membrane localization began to appear at 2 h, gradually spreading to more cells over time; at 8 h, the majority of cells already exhibited plasma membrane P86S localization. Upon warming to 37°C, plasma membrane localization persisted as long as 2.5 h but ER localization gradually became more evident and dominated at 7.5 h after warming. Similar P86S-EGFP aggregates were also seen in cells treated with thapsigargin before plasma membrane localization became predominant (Fig. 3). We have previously shown that P86S and ER residential protein calreticulin colocalize in HEK 293 cells (Yu et al. 2011a). As calreticulin is a molecular chaperone (Michalak et al. 2009), we tested whether calreticulin and aggregated P86S colocalize. Immunostaining of calreticulin in cells treated with low temperature or thapsigargin for 2 h showed that the P86S-EGFP aggregates and calreticulin did not colocalize, suggesting that calreticulin is not a molecular chaperone of P86S (Fig. 4).

Figure 3 Time course of rescue by thapsigargin under live cell imaging. HEK 293 cells stably expressing P86S-EGFP were treated with 1 μM thapsigargin for 7 h. Shown are the same live cells observed at the indicated times (in hours). Bar, 10 μm.

Figure 4 Calreticulin is not a P86S molecular chaperone. HEK 293 cells stably expressing P86S-EGFP were incubated at 27°C or treated with 1 μM thapsigargin for 2 h. Cells were fixed and immunostained for calreticulin (middle column) and counterstained with Hoechst 33352 (right column). Note that in cells incubated at 27°C or treated with thapsigargin, the aggregates of P86S-EGFP fluorescence (left column) and calreticulin fluorescence do not overlap. Bar, 10 μm.
Parallel western blot experiments on cells treated with low temperature showed that the amount of mature form of P86S increased at 2 h with a simultaneous decrease in that of the immature form (Fig. 5). At 7 h, however, the total amount of P86S, especially the immature form, was significantly decreased compared with that at the beginning of low-temperature treatment with similar levels of the mature form, suggesting degradation of the immature form of P86S-EGFP during the 4–7 h after low-temperature treatment. As the total amount of P86S-EGFP returned to pretreatment levels at 24 h, it appeared that the newly synthesized P86S-EGFP was correctly processed at low temperature. Western blot also confirmed that the mature form remained on the plasma membrane even at 3 h after warming. Thapsigargin and curcumin treatments also increased the mature form of P86S in 2–4 h. Similar to that in cells treated at low temperature, the immature form underwent significant degradation during the 4–7 h of treatment. We could not carry out the experiments longer due to toxicities of thapsigargin and curcumin. The lipophilic GCGR antagonist L-168,049 increased the amount of mature P86S-EGFP without a significant decrease in the immature form so that P86S-EGFP remained predominantly in the immature form, explaining the apparent lack of clear P86S-EGFP plasma membrane localization after L-168,049 treatment.

**Figure 5** Maturation of P86S by chaperones. HEK 293 cells stably expressing P86S-EGFP were incubated at 27°C for 2–24 h and then at 37°C for 3–7 h or treated with 1 μM thapsigargin or curcumin for 7 h or glucagon antagonist L-168,049 for 24–72 h. Cells were lysed at the indicated time and subjected to SDS–PAGE and western blotting with anti-EGFP or anti-actin.

**Function of trafficked P86S**

We tested whether the trafficked P86S would be functional by cAMP production and receptor internalization (Figs 6 and 7). Compared with HEK 293 cells expressing P86S-EGFP preincubated at the normal 37°C (with P86S stranded in the ER and only 12.9% on the plasma membrane as shown earlier), cells preincubated at 27°C for 24 h (with 76.8% of P86S on plasma membrane) produced significantly more cAMP upon stimulation by glucagon at 10–100 nM (Fig. 6). Similarly, in another experiment, cells pretreated with thapsigargin (48.7% of P86S on plasma membrane) produced significantly more cAMP upon stimulation by 100 nM glucagon. In parallel experiments, HEK 293 cells expressing P86S-EGFP were
pretreated at 27°C for 24 h and warmed to 37°C and treated with vehicle or glucagon (Fig. 7). The plasma membrane P86S-EGFP was internalized by glucagon like the WT GCGR. P86S-EGFP trafficked by thapsigargin did not internalize upon glucagon treatment.

Design of novel glucagon analogs

Glucagon and GCGR are highly homologous to GLP1 and GLP1 receptor (GLP1R). GCGR has not been resolved by crystallography but the N-terminal ECD of GLP1R bound with GLP1 has. Proline 90 in GLP1R (corresponding to proline 86 in GCGR) is in the binding pocket of GLP1R and GLP1 and interacts with alanine 25 of GLP1 (corresponding to alanine 19 in glucagon) (Runge et al. 2008). As replacing proline 86 in GCGR with serine decreases receptor activity, we hypothesized that changing alanine 19 in glucagon to another amino acid residue potentially restores the glucagon-stimulated signal transduction of P86S.

Based on molecular modeling (see Materials and methods), two novel glucagon analogs, peptide 1 and peptide 2, were synthesized, in which alanine 19 was replaced with serine or asparagine respectively (Fig. 8). The free hydroxyl group in serine and amino group in asparagine may also form a hydrogen bond with serine 86 in P86S.

Testing the potency of novel glucagon analogs

We tested whether the two rationally designed analogs would augment the signal transduction of P86S (Fig. 9). Compared with the native glucagon, both peptide 1 and peptide 2 were less effective in stimulating cAMP production by cells expressing P86S-EGFP either preincubated at 37°C (ER-stranded P86S) or 27°C (rescued P86S). Interestingly, cAMP production by cells pretreated at 27°C was invariably larger, regardless of which glucagon species was used, supporting that low temperature rescues the P86S function.

Discussion

Natural mutations of G-protein-coupled receptors are rare but cause various inherited or sporadic human diseases (Spiegel & Weinstein 2004, Tao 2006). Pathogenic mutations inappropriately activate or inactivate the receptors harboring them. The loss of receptor function by the inactivating mutations can be due to one or more abnormalities in the four mechanisms: receptor synthesis, receptor trafficking to the plasma membrane, ligand binding, and receptor activation of G proteins (Tao 2006). Among those, abnormal receptor trafficking is the most common mechanism for receptor inactivation. We have previously described for the first time an inactivating...
was measured. 

incorporating increasing concentrations. Cells were lysed and cAMP production was measured.

Figure 9 Signaling of rescued P86S stimulated by novel glucagon analogs. 

mutation (P86S) of the human GCGR that causes a novel human disease of hyperglucagonemia without glucagonoma syndrome, hypoglycemia, pancreatic α-cell hyperplasia, and pancreatic neuroendocrine tumors (Mahvash disease) (Yu et al. 2008, Zhou et al. 2009). It is interesting to note that the most severe feature of Mahvash disease, pancreatic neuroendocrine tumors, is an indirect effect of GCGR inactivation, namely, compensatory α-cell hyperplasia (Ouyang et al. 2011). The main mechanism of decreased P86S functionality is abnormal receptor trafficking; P86S is stranded in the ER rather than localized on the plasma membrane (Yu et al. 2011a). The second mechanism appears to be defective interaction with glucagon (Zhou et al. 2009). As α-cell hyperplasia is reversible in other circumstances (Webb et al. 2002, Gu et al. 2009) and there are no specific treatments for Mahvash disease (Yu et al. 2008, Ouyang et al. 2011), rescuing P86S function by chaperones or novel ligands may be a viable treatment strategy, which has the potential to revert the hypoglycemia and α-cell hyperplasia.

Our results demonstrate that on principle, P86S can be at least partially rescued by chaperones. Low temperature largely restored P86S plasma membrane localization while ER stressors and lipophilic GCGR antagonists partially achieved that, but osmotic chaperones had no effects. Our data further indicate that the rescued P86S can be functional as shown by the increased glucagon-stimulated cAMP production in cells with rescued P86S and the normal internalization of the rescued P86S by low temperature. It should not be taken for granted that P86S can be rescued. Whether a mutant receptor can be rescued by pharmacological chaperones is unpredictable and a mutant receptor is more often than not unrescuable; for example, only one of nine ER-stranded mutant vasopressin type 2 receptors is rescued even though most of them only have single amino acid mutations (Robben et al. 2006). That P86S is at least partially rescuable suggests that pharmacological chaperones are a potential treatment for Mahvash disease. It is not surprising that the chaperones had various effects on P86S rescue as the efficacy of pharmacological chaperones is also not quite predictable as shown by the variable efficacies of peptidomimetic chaperones on the same mutant GnRH receptor (Janovick et al. 2003).

Our study also elucidates to some degree the mechanisms for which pharmacological chaperones rescue P86S. Although the specifics of normal GCGR trafficking are not known, it is generally held that nascent proteins in the ER are folded with the help of molecular chaperones and adopt a particular 3-dimensional structure that guides their trafficking to distinct subcellular locations, including the plasma membrane (Conn et al. 2007). The seven transmembrane domains of the rat GCGR are required for cell surface expression, but the N-terminal ECD is not, nor are the four putative N-linked glycosylation sites on the N terminus (Unson et al. 1995). By contrast, we show in the current work that glycosylation inhibitor partially prevents normal plasma membrane localization of human GCGR. The role of GCGR glycosylation in receptor localization is thus not clear and needs to be clarified in future studies. Our data demonstrate that both WT GCGR and P86S exist in two forms, a mature larger form residing on the plasma membrane (predominant form of WT GCGR) and an immature smaller form stranded in the ER (predominant form of P86S), similar to mutant vasopressin type 2 receptors (Bernier et al. 2004). Upon low-temperature or thapsigargin treatment, the immature P86S would accumulate in aggregates that are devoid of calreticulin, a common molecular chaperone, with a concurrent increase in the amounts of mature P86S and a decrease
In summary, we have demonstrated that the P86S mutant GCGR is partially rescued by several pharmacological chaperones with restoration of receptor function to some degree. Our data provide proof-of-principle evidence that Mahvash disease can be potentially treated with pharmacological chaperones. The novel glucagon analogs, however, failed to interact with P86S more effectively.

**Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

**Funding**

The work was supported by National Institutes of Health grant DK071870 (R Y) and Cedars-Sinai Medical Center.

**Author contribution statement**

The study was designed by R Y, G-R C, and X L; experiments were carried out by R Y, G-R C, and X L; and data were analyzed by R Y, G-R C, X L, and J T K. The manuscript was drafted by R Y and approved by all authors.

**Acknowledgements**

The authors thank Dr Milton T Stubbs for help in designing the novel glucagon analogs.

**References**


**Author contribution statement**

The study was designed by R Y, G-R C, and X L; experiments were carried out by R Y, G-R C, and X L; and data were analyzed by R Y, G-R C, X L, and J T K. The manuscript was drafted by R Y and approved by all authors.

**Acknowledgements**

The authors thank Dr Milton T Stubbs for help in designing the novel glucagon analogs.

**References**


Journal of Molecular Endocrinology (2012) 49, 69–78 www.endocrinology-journals.org

Received in final form 17 May 2012
Accepted 8 June 2012
Made available online as an Accepted Preprint 12 June 2012

Downloaded from Bioscientifica.com at 01/19/2019 10:46:15AM via free access